Adeno-associated virus gene transfer in Morquio A disease – effect of promoters and sulfatase-modifying factor 1
By admin
Mucopolysaccharidosis (MPS) IVA is an autosomal recessive disorder caused by deficiency of the lysosomal enzyme N-acetylgalatosamine-6-sulfate sulfatase (GALNS), which leads to the accumulation of keratan sulfate and chondroitin 6-sulfate, mainly in bone. To explore the possibility of gene therapy for Morquio A disease, we transduced the GALNS gene into HEK293 cells, human MPS IVA fibroblasts and murine MPS IVA chondrocytes by using adeno-associated virus (AAV)-based vectors, which carry human GALNS cDNA. The effects of the promoter and the cotransduction with the sulfatase-modifying factor 1 gene (SUMF1) on GALNS activity levels was evaluated. Downregulation of the cytomegalovirus (CMV) immediate early enhancer/promoter was not observed for 10 days post-transduction. The eukaryotic promot…
Related Post
- Zinc Finger Protein Designed to Target 2-Long Terminal Repeat Junctions Interferes with Human Immunodeficiency Virus Integration - May 13th, 2012
- A Shield Against Chemotherapy - May 13th, 2012
- Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome - May 13th, 2012
- A paradigm shift in the delivery of services for diagnosis of inherited retinal disease - May 13th, 2012
- Interferon-alpha enhances antitumor activities of oncolytic adenovirus-mediated IL-24 expression in hepatocellular carcinoma - May 13th, 2012
- HIV Gene Therapy Safe Over Time (CME/CE) - May 6th, 2012
- Nanovector delivery of siRNA for cancer therapy - May 6th, 2012
- Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model - May 6th, 2012
- Interferon-? lipofection II. Mechanisms involved in cell death and bystander effect induced by cationic lipid-mediated interferon-? gene transfer to human tumor cells - May 6th, 2012
- MicroRNA silencing improves the tumor specificity of adenoviral transgene expression - May 6th, 2012
- Targeted therapy via oral administration of attenuated Salmonella expression plasmid-vectored Stat3-shRNA cures orthotopically transplanted mouse HCC - May 6th, 2012
- Gene Hunt Is On for Mental Disabilities in Children - May 6th, 2012
- Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning - May 6th, 2012
- MRI roadmap-guided transendocardial delivery of exon-skipping recombinant adeno-associated virus restores dystrophin expression in a canine model of Duchenne muscular dystrophy - May 6th, 2012
- Critical Variables affecting clinical-grade production of the self-inactivating gamma-retroviral vector for the treatment of X-linked severe combined immunodeficiency - May 6th, 2012
- Study: Gene Therapy for HIV Safe, But Effectiveness Still Unclear - May 6th, 2012
- April 2012 Advances: Additional Resources - May 6th, 2012
- Scientists find 10 subsets of breast cancer - April 29th, 2012
- Synthetic Biologics Appoints Michael Kaleko, M.D., Ph.D., as Scientific Director - April 29th, 2012
- Genetic test could pave the way for breast cancer 'magic bullets' - April 29th, 2012
- Researchers discover two new genetic loci for obesity - April 29th, 2012
- 'Genetic Fix' From AVI Biopharma Builds Key Muscle Function Protein - April 29th, 2012
- Genetic testing for drug intolerance - April 29th, 2012
- Brooklyn godsend for teen with rare genetic disorder - April 29th, 2012
- Genetic Technologies' Subsidiary Update - April 29th, 2012
- Will we ever correct diseases before birth? | Not Exactly Rocket Science - April 29th, 2012
- Amsterdam Molecular Therapeutics Receives Further Opinion on Glybera® Marketing Authorisation Application - April 29th, 2012
- Gene therapy helps woman to write - April 29th, 2012
- Greenwich gala celebrates cancer therapy breakthrough - April 29th, 2012
- Gene therapy group looks to new frontiers in fight against cancer - April 29th, 2012
- Video: Gene therapy reverses Parkinson's symptoms: study - April 29th, 2012
- New York Mesothelioma Lawyer Applauds Advances in Gene Therapy Cited in New Book - April 29th, 2012
- Gene Therapy Restores Sight to Three Patients - April 29th, 2012
- Global Gene Therapy Industry - April 29th, 2012
- Research and Markets: Breaking the Gene Therapy Barrier for Life-Threatening Red Blood Cell Disorders - April 29th, 2012
- Epirubicin potentiates recombinant adeno?associated virus type 2/5–mediated TRAIL expression in fibroblast?like synoviocytes and augments the antiarthritic effects of rAAV2/5?TRAIL - April 29th, 2012
- CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results - April 29th, 2012
- Prospects for gene transfer for clinical heart failure - April 29th, 2012
- Gene therapy for ventricular tachyarrhythmias - April 29th, 2012
- Activation of a glioma-specific immune response by oncolytic parvovirus Minute Virus of Mice infection - April 29th, 2012
July 31st, 2010
This author published 9679 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research